Drug Profile
NS 2359
Alternative Names: 372475; GSK 372475Latest Information Update: 11 Nov 2020
Price :
$50
*
At a glance
- Originator NeuroSearch
- Developer National Institute on Drug Abuse; Saniona; University of Pennsylvania
- Class Antidepressants; Drug withdrawal therapies; Nootropics; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cocaine-related disorders
- Discontinued Alcoholism; Attention-deficit hyperactivity disorder; Major depressive disorder
Most Recent Events
- 05 Nov 2020 Saniona and University of Pennsylvania, Treatment Research Center (TRC) discontinue the research collaboration to develop NS 2359 in Cocaine Cocaine-related disorders
- 07 Oct 2020 Saniona, University of Pennsylvania and the Dana Foundation completes a phase II trial for Cocaine abuse in USA (PO) (NCT02798627)
- 23 Jan 2019 The University of Pennsylvania Treatment Research Center (TRC) plans to continue the ongoing phase II study for NS 2359 in cocaine addiction at a higher dose